Picture a med-check you will run a hundred times in your first year. A 23-year-old comes in for a follow-up on her sertraline. Mood is better. Sleep is fine. As she is packing up, she mentions, almost as an aside, that she quit cigarettes and switched to nicotine pouches. She pulls a small round tin out of her bag, tells you she keeps one in most of the day at work, and asks the question that is going to come up more and more often in your career: “They’re safer, right?”
That scenario is not hypothetical. It is the case that opens Dr. Jasleen Kaur’s clinical update in the July/August/September 2026 issue of The Carlat Addiction Treatment Report, and it is worth sitting with, because the honest answer is “sort of, but not the way you think,” and the follow-up questions are where the real clinical work lives. If you are studying to become a PMHNP, nicotine pouches are one of those topics that will never get their own lecture in your program and will show up in your exam room within your first month of practice.
What a nicotine pouch actually is
Nicotine pouches are small white packets, roughly the size of a piece of gum, that hold nicotine inside an inert filler. The user tucks one between the upper lip and gum, and nicotine absorbs slowly across the oral mucosa. There is no smoke, no vapor, and unlike traditional dip or chew, no spitting. The big brands are Zyn, On!, and Velo, and the marketing leans hard on the phrase “tobacco-free,” which is technically accurate because the nicotine is extracted or synthesized rather than delivered in shredded leaf.
The pharmacology matters for boards and for practice. Carlat notes that pouches typically contain 2 to 9 mg of nicotine each, though some high-strength imports deliver as much as 50 mg in a single pouch. Serum nicotine peaks roughly 20 to 30 minutes after placement. That is much slower than a cigarette, which spikes nicotine in the brain within seconds, and roughly comparable to a nicotine lozenge. At standard strengths, overall nicotine exposure lands near what a lozenge delivers. At the higher strengths, it starts to approach cigarette-level exposure.
The regulatory backdrop you should be able to explain
On January 16, 2025, the FDA authorized the marketing of 20 Zyn products through the premarket tobacco product application pathway, the first time the agency had authorized any nicotine pouch. The FDA’s reasoning was explicit: because these products contain substantially lower amounts of harmful constituents than cigarettes and most smokeless tobacco, they pose a lower risk of cancer and other serious conditions for adults who switch completely. The agency later allowed Zyn to carry a specific modified-risk claim comparing it favorably to cigarettes on mouth cancer, heart disease, lung cancer, stroke, and emphysema.
Read that carefully, because the word doing all the work is “instead.” The FDA’s public health standard is built around adult smokers who switch completely. It says nothing about safety for someone who has never smoked, nothing about someone who uses pouches and cigarettes together, and nothing about the 15-year-old whose first exposure to nicotine is a wintergreen pouch. That distinction between “less harmful than cigarettes” and “safe” is exactly the gap your patients will fall into, and it is your job to close it.

Who is using them, and how fast that is changing
The demographic answer from Carlat is that the patients you are most likely to see using pouches are adults aged 18 to 40 with a history of smoking or vaping. Many are current or former smokers trying to cut down or find a workaround for places they cannot smoke. But a meaningful share are people who never used combustible tobacco at all, and that share is growing.
The youth numbers are where the story gets urgent. A 2025 analysis in JAMA Network Open by Dae-Hee Han and colleagues, drawing on the Monitoring the Future survey of more than 10,000 10th and 12th graders, found that past-30-day nicotine pouch use among high schoolers nearly doubled in a single year, from about 3 percent in 2023 to 5.4 percent in 2024. That jump happened while teen vaping was actually declining. The CDC’s National Youth Tobacco Survey tells the same story from a different angle: in 2024, pouches were the second most commonly used nicotine product among middle and high school students, behind only e-cigarettes, and among the students who used them, more than one in four reported use on 20 or more of the past 30 days. More than 90 percent used flavored products, with mint leading the way.
Carlat’s synthesis of the literature is blunt about why. Flavors drive initiation, especially in younger users. The products are discreet enough to use in class or at work. And the “tobacco-free” label does exactly what it was designed to do: most users, according to the survey data Carlat cites, chose pouches because they believed them to be safer than cigarettes.
So, are they safe?
Here is the balanced answer Carlat lays out, and it is the one you should be ready to give in the room. Pouches expose users to far fewer harmful chemicals than cigarettes because nothing is burning. Combustion is what generates the tar, carbon monoxide, and most of the carcinogens that kill smokers. Take combustion out of the picture and you have removed the majority of the harm.
But not all of it. Short-term effects include oral irritation and mucosal changes at the site where the pouch sits. Laboratory analyses have found heavy metals, formaldehyde, and tobacco-specific nitrosamines in some products. And the long-term picture is simply unknown, because these products have only been on the U.S. market for about a decade. Chronic nicotine exposure on its own carries cardiovascular, metabolic, and oral health consequences, and pouches are a very efficient way to deliver chronic nicotine exposure.
That last point is the one Carlat wants you to internalize. Because a pouch is slow-onset and discreet, users do not get the sharp reward and then put it away the way a smoker finishes a cigarette. They leave one in for 10 to 30 minutes, replace it, and repeat. Some people use them nearly continuously through the waking day. Dual use is also common: cigarettes or vaping in one setting, pouches in another. In that pattern, the pouch is not a step down from smoking. It is a second nicotine source stacked on top of the first, and total nicotine intake goes up, not down. The harm-reduction argument only works if the switch is complete.
The drug interaction that will show up on your boards
Now for the part of this topic that is pure psychopharmacology, and the reason I would put it on a flashcard tonight. When a patient switches from cigarettes to pouches, they lose the CYP1A2 induction that came with smoke.
Lock in the mechanism, because exam writers love it. Nicotine is not the inducer. The polycyclic aromatic hydrocarbons in tobacco smoke are. Smoking ramps up CYP1A2 activity, which means smokers metabolize CYP1A2 substrates faster and need higher doses to reach the same serum level. Stop the smoke, and the induction fades over days to a couple of weeks. Serum levels of those substrates climb, sometimes dramatically, even though the patient has not changed a single prescription.
The substrate that matters most in psychiatry is clozapine. Olanzapine is next on the list, and fluvoxamine, duloxetine, and caffeine are all affected too. Carlat makes the point directly: whenever a patient moves from combustible tobacco to any smokeless nicotine product, including pouches, the clinician has to anticipate rising levels of CYP1A2-metabolized drugs, and for a narrow-therapeutic-index medication like clozapine that can mean seizures, sedation, hypotension, or worse.
Here is the trap. The patient in front of you says, “I still use nicotine, I just switched to pouches.” A clinician who is thinking “nicotine” rather than “smoke” will assume nothing has changed. The correct response is to treat a switch to pouches the same way you would treat smoking cessation: expect the clozapine level to rise, plan to check a level, and be ready to reduce the dose. If you want the full workup on how quitting smoking pushes clozapine toward toxicity, we covered it in an earlier post on this site, and the two topics fit together like puzzle pieces.

How to have the conversation
The clinical skill here is not memorizing statistics. It is asking the right question and then responding in a way that keeps the patient in the room. Carlat offers language that is worth borrowing nearly word for word.
Start by asking about nicotine specifically, and name pouches. Many patients will not volunteer it, partly because they do not think of pouches as “tobacco” and partly because nobody has ever asked. A simple version is: “What kinds of nicotine are you using, like pouches, vaping, or cigarettes?” Put that question into your intake template now, while you are still a student, and it will be automatic by the time you are credentialed.
When the patient asks whether pouches are safe, Carlat suggests something close to: “Pouches are probably less harmful than cigarettes because there is no smoke, but they are not risk-free, and you are still getting nicotine and other chemicals.” That framing is credible precisely because it concedes the true part.
If the patient is using pouches as harm reduction, shift the focus from the product to the behavior. Something like: “If you switch completely from cigarettes to pouches, that likely does reduce harm. The problem is that most people end up using both, which cancels out most of the benefit.” Then ask about escalation: because they can be used anywhere, a lot of people use them all day, and that tends to make nicotine dependence stronger rather than weaker.
And if the goal is to quit nicotine entirely, pivot to what actually works. Varenicline, combination nicotine replacement, and bupropion all have trial evidence for cessation. Pouches do not. That is the Carlat verdict in one sentence: pouches probably cut combustion exposure, but their convenience drives continuous use and higher total nicotine intake, so ask specifically about them, correct the assumption that “tobacco-free” means harmless, and steer patients who want to quit toward varenicline or NRT.
Why this matters for you specifically
You are entering practice at a moment when the nicotine landscape is shifting under everyone’s feet. Vaping is drifting down among teens. Pouches are climbing. The FDA has put an official lower-risk stamp on the leading brand, and the marketing machinery is treating that as a green light. Your patients, especially the young adults and adolescents who make up so much of a PMHNP’s caseload, are going to arrive with a tin in their pocket and a belief that it does not count.
For the boards, the testable material is clean and specific. Know that smoke, not nicotine, is the CYP1A2 inducer. Know that clozapine and olanzapine are the psychiatric drugs most affected, and that any switch away from combustible tobacco, including to pouches, means anticipating a rising level. Know that varenicline, combination NRT, and bupropion are the evidence-based cessation options and that pouches are not one of them. Know that oral nicotine peaks in 20 to 30 minutes, and that slow onset does not mean lower dependence when the product is used all day.
For practice, the lesson is broader. Every generation of nicotine products has arrived with a story about being cleaner, safer, or not really tobacco. Your value as a clinician is not in scolding people who bought that story. It is in asking the question nobody else asked, telling the truth in a way that keeps the door open, and knowing which of your prescriptions will quietly change the day your patient’s habits do.
That is the kind of clinical thinking PMHNP Review is built to develop: not memorizing isolated facts, but understanding how pharmacology, epidemiology, and a two-minute conversation fit together in a real exam room. If you are preparing for your ANCC or AANP boards and want study material that treats you like the clinician you are about to become, visit https://pmhnpreview.org and see how we can help you get there.
